ClinicalTrials.gg
RecruitingNCT06153251Updated Mar 18, 2026

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1 interventional study of BMS-986453 and Fludarabine in Relapsed and/or Refractory Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Recruiting at 19 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
187
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.

Planned enrollment
34th of 108
187 · median 83
Started
2024
with 6 others
Phase 1
40 of 149
2 open now
Primary completion
2030-05
later than 15 of 17 live
Registered
138th of 149
by date

Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 34th largest by planned enrollment of the 108 interventional ones that give a count, is one of 7 that started in 2024, is one of 40 in phase 1, reaches primary completion later than 15 of the 17 other live ones, and was the 138th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Multiple Myeloma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

03

Conditions studied

  • Relapsed and/or Refractory Multiple Myeloma

Browse trials for

Keywords

  • Dual Targeting
  • BCMAxGPRC5D
  • GPRC5DxBCMA
  • BMS-986453
  • CAR T
  • CART
  • Multiple Myeloma
  • Relapsed and/or Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a diagnosis of multiple myeloma with disease.
  • Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.
  • Participants in Part A and Part B Cohort 1 and in Part B Cohort 2 must have relapsed/refractory multiple myeloma and received previous antimyeloma therapy, including a proteasome inhibitor and an immunomodulatory agent.
  • Participants must have an (ECOG) performance status of 0 or 1.
  • Participants must have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.
  • Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or amyloidosis.
  • Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis.
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
187 participants (estimated)

Study arms

  • Experimental
    Administration of BMS-986453

    Drug: BMS-986453 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • DrugBMS-986453

    Specified dose on specified days

  • Specified dose on specified days

    Also known as: FludAra, Oforta

  • Specified dose on specified days

    Also known as: Cytoxan, Cytoxan Lyophilized, Neosar

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (AEs)

    Time frame: Up to 4 years

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 4 years

  3. Number of participants with AEs leading to discontinuation

    Time frame: Up to 4 years

  4. Number of participants with AEs leading to death

    Time frame: Up to 4 years

  5. Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Up to 4 years

Secondary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to 4 years

  2. Time of maximum observed concentration (Tmax)

    Time frame: Up to 4 years

  3. Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))

    Time frame: Up to 4 years

  4. Overall response rate (ORR)

    Time frame: Up to 4 years

  5. Complete response rate (CRR)

    Time frame: Up to 4 years

  6. Number of participants with very good partial response (VGPR) or better

    Time frame: Up to 4 years

  7. Progression-free survival (PFS)

    Time frame: Up to 4 years

  8. Overall survival (OS)

    Time frame: Up to 4 years

  9. Time to response (TTR)

    Time frame: Up to 4 years

  10. Time to complete response (TTCR)

    Time frame: Up to 4 years

  11. Duration of response (DOR)

    Time frame: Up to 4 years

  12. Duration of complete response (DOCR)

    Time frame: Up to 4 years

  13. Persistence of BMS-986453 in peripheral blood

    Defined as a transgene count greater than or equal to the lower limit of detection (LLOD)

    Time frame: Up to 4 years

  14. Expansion rate

    Defined as Cmax divided by Tmax

    Time frame: Up to 4 years

07

Study locations

18 of 19 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
    • Luciano Costa, Site 0001 · Contact205-934-9695
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
    Recruiting
    • MURALI JANAKIRAM, Site 0003 · Contact626-201-5710
  • UCSF Helen Diller Medical Center at Parnassus Heights
    San Francisco, California 94143, United States
    Recruiting
    • Alfred Chung, Site 0011 · Contact000-000-0000
  • Stanford University Medical Center
    Stanford, California 94305, United States
    Recruiting
    • Surbhi Sidana, Site 0006 · Contact650-723-0822
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
    Recruiting
    • Tara Gregory, Site 0013 · Contact720-754-4800
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
    Recruiting
    • Noffar Bar, Site 0005 · Contact000-000-0000
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Doris Hansen, Site 0016 · Contact601-812-3214
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Clifton Mo, Site 0023 · Contact202-689-9961
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Adriana Rossi, Site 0010 · Contact646-962-6500
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Sham Mailankody, Site 0004 · Contact646-608-3712
  • Local Institution - 0008
    Nashville, Tennessee 37203, United States
    Not yet recruiting
    • Site 0008 · Contact
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
    • Jesus Berdeja, Site 0020 · Contact615-329-0570
  • Swedish Medical Center
    Seattle, Washington 98104, United States
    Recruiting
    • Swathi Namburi, Site 0012 · Contact206-386-6738
  • Hôpital Saint-Louis
    Paris, 75010, France
    Recruiting
    • Bertrand Arnulf, Site 0019 · Contact33142499472
  • Universitaetsklinikum Koeln
    Cologne, 50937, Germany
    Recruiting
    • Christof Scheid, Site 0017 · Contact492214786296
  • Universitaetsklinikum Heidelberg
    Heidelberg, D-69120, Germany
    Recruiting
    • Marc-Steffen Raab, Site 0021 · Contact496221565427
  • Universitaetsklinikum Wuerzburg
    Würzburg, 97080, Germany
    Recruiting
    • Hermann Einsele, Site 0018 · Contact+4994120140202
  • Clinica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
    Recruiting
    • Paula Rodriguez Otero, Site 0015 · Contact+0034948254000 0 000
  • Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
    Salamanca, 37007, Spain
    Recruiting
    • Maria Victoria Mateos Manteca, Site 0014 · Contact34923291100
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for May 2030, 75 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 75 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2023
First posted
Dec 1, 2023
StartActual
Jan 23, 2024
Primary completionEst.
May 2, 2030
CompletionEst.
May 2, 2030
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153251
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Jan 23, 2024
Primary completion
May 2, 2030 (estimated)
Completion
May 2, 2030 (estimated)
Last update
Mar 18, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion